Donoghue Forlines LLC Incyte Corp Transaction History

Donoghue Forlines LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$60.95 - $75.51 $139,819 - $173,219	2,294 Added 77.74%	5,245 $326,000
Q1 2023 May 08, 2023	BUY	$70.23 - $86.01 $207,248 - $253,815	2,951 New	2,951 $213,000
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $618,541 - $746,802	-9,369 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$63.34 - $74.11 $380 - $444	6 Added 0.06%	9,369 $688,000
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $170,301 - $208,369	2,480 Added 36.03%	9,363 $644,000
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $549,745 - $602,468	6,883 New	6,883 $579,000
Q2 2019 Jul 23, 2019	SELL	$73.52 - $88.7 $2.38 Million - $2.87 Million	-32,306 Closed	0 $0
Q1 2019 Apr 12, 2019	BUY	$63.56 - $88.17 $2.05 Million - $2.85 Million	32,306 New	32,306 $2.78 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Donoghue Forlines LLC, based on Form 13F filings with the SEC.

Stay updated on Donoghue Forlines LLC with notifications on news.